Summary

The companion diagnostics market is projected to reach USD 11.57 billion by 2031, from USD 6.31 billion in 2026, with a CAGR of 12.9%. This growth is primarily driven by increasing oncology biomarker testing, expanding approvals of targeted therapies and immunotherapies, and rising pharmaceutical–diagnostic co-development activities. Market growth is further supported by advancements in molecular diagnostics technologies, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry, and in situ hybridization, along with increased demand for personalized treatment selection. However, high development and validation costs, complex regulatory pathways, reimbursement limitations, and variability in biomarker testing infrastructure across regions are expected to restrain market growth to a certain extent.

“Assays, kits & reagents accounted for the largest share of the companion diagnostics market, by product & service, in 2025.”
In 2025, assays, kits & reagents accounted for the largest share due to their extensive use in biomarker detection, mutation analysis, therapy selection, and routine molecular testing workflows. Their recurring demand, compatibility with high-throughput testing platforms, and increasing adoption in oncology-focused precision medicine applications continue to support segment growth. Additionally, rising approvals of companion diagnostic assays linked to targeted therapies and immunotherapies are further strengthening the dominance of this segment.
“PCR accounted for a major share of the companion diagnostics market, by technology, in 2025.”
In 2025, PCR accounted for a major share due to its high analytical sensitivity, shorter turnaround time, broad clinical adoption, and strong regulatory acceptance in biomarker-driven testing. PCR technologies are widely used for mutation detection and targeted therapy selection across multiple oncology indications. Additionally, growing use of multiplex PCR assays and increasing demand for rapid molecular testing continue to support the segment’s leading market position globally.
“Asia Pacific is expected to be the fastest-growing market for companion diagnostics during the forecast period.”
During the forecast period, the Asia Pacific region is projected to register the highest CAGR due to increasing cancer incidence, expanding healthcare infrastructure, rising investments in molecular diagnostics, and growing adoption of precision medicine approaches. Growth is further supported by improving access to advanced oncology care, expansion of pharmaceutical clinical trials, and increasing presence of regional and global diagnostic companies across China, Japan, India, South Korea, and Southeast Asia.

Companies Profiled
・F. Hoffmann-La Roche AG
・Agilent Technologies, Inc
・Qiagen N.V.
・Thermo Fisher Scientific, Inc.
・Abbott Laboratories
・Almac Group
・Danaher Corporation
・Illumina Inc
・Biomerieux Sa
・Myriad Genetics, Inc
・Sysmex Corporation
・Guardant Health, Inc.
・Icon Plc
・Quest Diagnostics
・Amoy Diagnostics Co., Ltd
・Tempus Ai, Inc
・Caris Life Sciences, Inc.

Research Coverage
This research report categorizes the companion diagnostics market by product & service, technology, indication, sample, end user, drug class, application, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the protein expression market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the protein expression market. This report covers competitive analysis of top players and upcoming startups in the protein expression market ecosystem.

Key Benefits of Buying this Report
The report will help market leaders and new entrants by providing the closest approximations of revenue numbers for the overall companion diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following points:
・Analysis of key drivers, including increasing adoption of precision medicine, expanding targeted therapy pipelines, rising oncology biomarker testing volumes, growing pharmaceutical–diagnostic partnerships, and increasing demand for personalized treatment approaches; restraints including high assay development costs, reimbursement limitations, and regulatory complexities; and challenges including standardization issues, biomarker validation complexities, and limited molecular testing infrastructure in emerging regions.
・Product Development/Innovation: Detailed insights on newly launched companion diagnostic assays, biomarker testing technologies, liquid biopsy platforms, NGS solutions, and therapy-linked molecular testing workflows.
・Market Development: Comprehensive information about lucrative markets — the report analyzes the companion diagnostics market across various regions.
・Market Diversification: Exhaustive information about product portfolios, technology developments, regulatory approvals, collaborations, partnerships, acquisitions, and investments in the companion diagnostics market.
・Competitive Assessment: In-depth assessment of market shares, growth strategies, technology capabilities, and service offerings of leading players such as F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Illumina Inc., bioMérieux SA, Sysmex Corporation, and Guardant Health, Inc.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 STUDY SCOPE 41
1.3.1 MARKETS COVERED & REGIONAL SCOPE 41
1.3.2 INCLUSIONS & EXCLUSIONS 42
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 43
1.4 STAKEHOLDERS 43
1.5 SUMMARY OF CHANGES 43
2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 47
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 48
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 COMPANION DIAGNOSTICS MARKET OVERVIEW 50
3.2 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 50
3.3 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 51
3.4 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2026 VS. 2031 51
3.5 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2026 VS. 2031 52
3.6 COMPANION DIAGNOSTICS MARKET, BY DRUG ASSOCIATED WITH CDX, 2026 VS. 2031 52
3.7 COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2026 VS. 2031 53
3.8 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4 MARKET OVERVIEW 54
4.1 INTRODUCTION 54
4.2 MARKET DYNAMICS 55
4.2.1 DRIVERS 55
4.2.1.1 Increasing adoption of precision medicine and targeted therapies 55
4.2.1.2 Growing investments in genomics, molecular diagnostics, and biomarker discovery 56
4.2.1.3 Expanding pharmaceutical-diagnostic co-development partnerships 57
4.2.2 RESTRAINTS 58
4.2.2.1 High development, clinical validation, and regulatory approval costs 58
 
4.2.3 OPPORTUNITIES 59
4.2.3.1 Expansion of liquid biopsy and non-invasive companion diagnostics 59
4.2.3.2 AI-driven biomarker interpretation and digital pathology integration 59
4.2.4 CHALLENGES 60
4.2.4.1 Regulatory complexity associated with simultaneous drug-diagnostic approvals 60
4.3 UNMET NEEDS & WHITE SPACES 61
4.3.1 UNMET NEEDS IN COMPANION DIAGNOSTICS MARKET 61
4.3.2 WHITE SPACE OPPORTUNITIES 63
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 64
4.4.1 INTERCONNECTED MARKETS 64
4.4.2 CROSS-SECTOR OPPORTUNITIES 65
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 66
4.5.1 KEY MOVES & STRATEGIC FOCUS 67
5 INDUSTRY TRENDS 68
5.1 PORTER’S FIVE FORCES ANALYSIS 68
5.1.1 BARGAINING POWER OF SUPPLIERS 69
5.1.2 BARGAINING POWER OF BUYERS 69
5.1.3 THREAT OF NEW ENTRANTS 69
5.1.4 THREAT OF SUBSTITUTES 70
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.2 MACROECONOMIC OUTLOOK 70
5.2.1 INTRODUCTION 70
5.2.2 GDP TRENDS & FORECAST 70
5.2.3 TRENDS IN GLOBAL COMPANION DIAGNOSTICS INDUSTRY 73
5.3 SUPPLY CHAIN ANALYSIS 74
5.4 VALUE CHAIN ANALYSIS 76
5.5 ECOSYSTEM ANALYSIS 78
5.6 PRICING ANALYSIS 80
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026 80
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024–2026 81
5.6.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY TYPE, 2024–2026 82
5.7 TRADE ANALYSIS 83
5.7.1 IMPORT SCENARIO (HS CODE 3822) 83
5.7.2 EXPORT SCENARIO (HS CODE 3822) 83
5.8 KEY CONFERENCES & EVENTS, 2026–2027 84
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85
5.10 INVESTMENT & FUNDING SCENARIO 86
 
5.11 IMPACT OF US TARIFFS—COMPANION DIAGNOSTICS MARKET 86
5.11.1 INTRODUCTION 86
5.11.2 KEY TARIFF RATES 87
5.11.3 PRICE IMPACT ANALYSIS 87
5.11.4 IMPACT ON COUNTRIES/REGIONS 88
5.11.4.1 North America 88
5.11.4.2 Europe 88
5.11.4.3 Asia Pacific 89
5.11.5 IMPACT ON END-USE INDUSTRIES 89
5.11.5.1 Hospital and cancer centers 89
5.11.5.2 Pharmaceutical and biopharmaceutical companies 90
5.11.5.3 Other end users 90
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91
6.1 KEY EMERGING TECHNOLOGIES 91
6.1.1 NEXT-GENERATION SEQUENCING (NGS)-BASED COMPREHENSIVE GENOMIC PROFILING 91
6.1.2 LIQUID BIOPSY (CFDNA/CTDNA TESTING) 91
6.2 COMPLEMENTARY TECHNOLOGIES 92
6.2.1 BIOINFORMATICS & AI-DRIVEN CLINICAL INTERPRETATION 92
6.2.2 MULTIPLEX PCR/QPCR PLATFORMS 92
6.3 ADJACENT TECHNOLOGIES 93
6.3.1 DIGITAL PATHOLOGY & AI-BASED IMAGING 93
6.4 TECHNOLOGY/PRODUCT ROADMAP 93
6.5 PATENT ANALYSIS 95
6.5.1 LIST OF MAJOR PATENTS 96
6.6 FUTURE APPLICATIONS 96
6.7 IMPACT OF AI/GENERATIVE AI ON COMPANION DIAGNOSTICS MARKET 97
6.7.1 INTRODUCTION 97
6.7.2 TOP USE CASES & MARKET POTENTIAL 98
6.7.3 KEY COMPANIES IMPLEMENTING AI 99
6.7.4 FUTURE OF AI 99
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 100
7.1 REGIONAL REGULATIONS & COMPLIANCE 100
7.1.1 REGULATORY ANALYSIS 100
7.1.1.1 North America 100
7.1.1.1.1 US 100
7.1.1.1.2 Canada 100
 
7.1.1.2 Europe 100
7.1.1.2.1 Germany 101
7.1.1.2.2 UK 102
7.1.1.2.3 France 102
7.1.1.2.4 Italy 102
7.1.1.3 Asia Pacific 102
7.1.1.3.1 China 102
7.1.1.3.2 Japan 103
7.1.1.3.3 India 103
7.1.1.3.4 Australia 103
7.1.1.4 Latin America 104
7.1.1.4.1 Brazil 104
7.1.1.4.2 Mexico 105
7.1.1.5 Middle East 105
7.1.1.5.1 Africa 105
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
7.2 SUSTAINABILITY INITIATIVES 107
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES 107
7.2.1.1 Eco-friendly initiatives 108
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 108
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 110
8.1 DECISION-MAKING PROCESS 110
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 110
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
8.2.2 BUYING CRITERIA 111
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 113
8.5 MARKET PROFITABILITY 114
8.5.1 REVENUE POTENTIAL 115
8.5.2 COST DYNAMICS 115
9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 116
9.1 INTRODUCTION 117
9.2 ASSAYS, KITS, AND REAGENTS 117
9.2.1 INCREASING ROUTINE USE OF BIOMARKER-BASED TESTING FOR TARGETED THERAPY AND IMMUNOTHERAPY SELECTION 117
9.3 INSTRUMENTS/SYSTEMS 122
9.3.1 RISING ADOPTION OF AUTOMATED MOLECULAR, PATHOLOGY, AND NGS PLATFORMS TO SUPPORT STANDARDIZED AND SCALABLE CDX TESTING 122
 
9.4 SOFTWARE & SERVICES 126
9.4.1 INCREASING DEMAND FOR HIGH-VALUE NGS INTERPRETATION, LIQUID BIOPSY SERVICES, PHARMA CDX CO-DEVELOPMENT, AND CLINICALLY ACTIONABLE REPORTING 126
10 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE 131
10.1 INTRODUCTION 132
10.2 TISSUE SAMPLES 132
10.2.1 CONTINUED DOMINANCE OF TISSUE-BASED BIOMARKER TESTING IN ONCOLOGY TREATMENT SELECTION 132
10.3 BLOOD SAMPLES 136
10.3.1 RAPID ADOPTION OF LIQUID BIOPSY AND CIRCULATING TUMOR DNA-BASED COMPANION DIAGNOSTICS TO DRIVE MARKET 136
10.4 OTHER SAMPLE TYPES 140
11 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 144
11.1 INTRODUCTION 145
11.2 POLYMERASE CHAIN REACTION 146
11.2.1 PREFERENCE FOR COST-EFFECTIVE, CLINICALLY ESTABLISHED SINGLE-GENE/HOTSPOT MUTATION TESTING DRIVES MARKET 146
11.3 IN SITU HYBRIDIZATION 150
11.3.1 NEED FOR TISSUE-BASED DETECTION OF GENE AMPLIFICATION, REARRANGEMENTS, AND EXPRESSION-LINKED THERAPY SELECTION DRIVE MARKET 150
11.4 NEXT-GENERATION SEQUENCING 154
11.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET 154
11.5 IMMUNOHISTOCHEMISTRY 158
11.5.1 STRONG USE OF TISSUE-BASED PROTEIN-EXPRESSION TESTING FOR IMMUNO-ONCOLOGY AND TARGETED THERAPY SELECTION 158
11.6 OTHER TECHNOLOGIES 162
12 COMPANION DIAGNOSTICS MARKET, BY INDICATION 166
12.1 INTRODUCTION 167
12.2 CANCER 167
12.2.1 LUNG CANCER 172
12.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption 172
12.2.2 BREAST CANCER 175
12.2.2.1 Wide prevalence of breast cancer among women contributes to the large market size of the segment 175
12.2.3 LEUKEMIA & LYMPHOMA 179
12.2.3.1 Precision profiling of targeted alterations in hematologic malignancies 179
 
12.2.4 COLORECTAL CANCER 182
12.2.4.1 Integration of biomarker testing for targeted and immunotherapy selection 182
12.2.5 MELANOMA 185
12.2.5.1 High immunotherapy and targeted therapy use based on molecular status 185
12.2.6 OTHER CANCERS 188
12.3 NEUROLOGICAL DISEASES 191
12.3.1 RISING BURDEN OF NEURODEGENERATIVE DISEASES TO DRIVE MARKET 191
12.4 CARDIOVASCULAR DISEASES 194
12.4.1 RISING GLOBAL INCIDENCE OF CARDIOVASCULAR PATIENTS TO EXPEDITE GROWTH 194
12.5 INFECTIOUS DISEASES 197
12.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH 197
12.6 OTHER INDICATIONS 200
13 COMPANION DIAGNOSTICS MARKET VOLUME ANALYSIS FOR CANCER, BY REGION (NUMBER OF TESTS) 204
14 COMPANION DIAGNOSTICS MARKET, BY APPLICATION 205
14.1 INTRODUCTION 206
14.2 CLINICAL DIAGNOSTICS 206
14.2.1 INCREASING USE OF CDX TESTING FOR REAL-TIME THERAPY SELECTION IN ONCOLOGY AND PRECISION MEDICINE 206
14.3 RESEARCH USE 209
14.3.1 RISING BIOMARKER DISCOVERY AND PHARMA-LED DRUG–DIAGNOSTIC CO-DEVELOPMENT PROGRAMS 209
15 COMPANION DIAGNOSTICS MARKET, BY END USER 213
15.1 INTRODUCTION 214
15.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 214
15.2.1 RISING PHARMA-LED DRUG–DIAGNOSTIC CO-DEVELOPMENT FOR TARGETED THERAPIES AND IMMUNOTHERAPIES DRIVES MARKET 214
15.3 REFERENCE LABORATORIES 218
15.3.1 INCREASING DEMAND FOR OUTSOURCED HIGH-COMPLEXITY MOLECULAR AND GENOMIC CDX TESTING 218
15.4 CONTRACT RESEARCH ORGANIZATIONS 221
15.4.1 INCREASING USE OF BIOMARKER-DRIVEN CLINICAL TRIALS AND CDX-ENABLED DRUG DEVELOPMENT PROGRAMS 221
15.5 OTHER END USERS 224
 
16 COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH CDX 228
16.1 INTRODUCTION 229
16.2 MONOCLONAL ANTIBODIES 229
16.2.1 RISING USE OF BIOMARKER-GUIDED MONOCLONAL ANTIBODY THERAPIES IN ONCOLOGY AND IMMUNO-ONCOLOGY 229
16.3 CELL & GENE THERAPY 232
16.3.1 INCREASING NEED FOR GENETIC, ANTIGEN, AND PATIENT-ELIGIBILITY TESTING IN ADVANCED PERSONALIZED THERAPIES 232
17 COMPANION DIAGNOSTICS MARKET, BY REGION 236
17.1 INTRODUCTION 237
17.2 NORTH AMERICA 237
17.2.1 US 243
17.2.1.1 Presence of advanced healthcare infrastructure to augment growth 243
17.2.2 CANADA 246
17.2.2.1 Expanding public oncology testing infrastructure and growing biomarker-based cancer care 246
17.3 EUROPE 250
17.3.1 GERMANY 253
17.3.1.1 Advanced molecular pathology infrastructure and strong oncology testing adoption 253
17.3.2 UK 257
17.3.2.1 NHS-led genomic medicine infrastructure and national test directory-based access 257
17.3.3 FRANCE 260
17.3.3.1 National cancer programs and structured molecular oncology networks 260
17.3.4 ITALY 264
17.3.4.1 Expanding molecular oncology adoption across regional cancer centers 264
17.3.5 SWITZERLAND 268
17.3.5.1 High-value precision medicine environment and strong pharma-diagnostics presence 268
17.3.6 SPAIN 271
17.3.6.1 Increasing adoption of biomarker-guided oncology across public hospital networks 271
17.3.7 REST OF EUROPE 275
17.4 ASIA PACIFIC 279
17.4.1 CHINA 284
17.4.1.1 Large oncology patient pool and rapid expansion of domestic precision medicine infrastructure 284
17.4.2 JAPAN 287
17.4.2.1 Universal healthcare reimbursement policy to foster growth 287
17.4.3 INDIA 291
17.4.3.1 Increased private and public investments to bolster growth 291
17.4.4 SOUTH KOREA 294
17.4.4.1 Advanced healthcare infrastructure and strong adoption of precision oncology technologies 294
17.4.5 AUSTRALIA 297
17.4.5.1 Strong oncology care infrastructure and high biomarker testing need in melanoma and solid tumors 297
17.4.6 REST OF ASIA PACIFIC 300
17.5 LATIN AMERICA 304
17.5.1 BRAZIL 307
17.5.1.1 Largest oncology patient pool in Latin America and growing adoption of precision oncology in private healthcare 307
17.5.2 MEXICO 310
17.5.2.1 Expanding oncology care networks and increasing use of biomarker testing in urban cancer centers 310
17.5.3 REST OF LATIN AMERICA 313
17.6 MIDDLE EAST & AFRICA 316
17.6.1 GCC COUNTRIES 320
17.6.1.1 Growing public healthcare funding to drive market 320
17.6.2 REST OF MIDDLE EAST & AFRICA 323
18 COMPETITIVE LANDSCAPE 327
18.1 INTRODUCTION 327
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 327
18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET 327
18.3 REVENUE ANALYSIS, 2023–2025 329
18.4 MARKET SHARE ANALYSIS, 2025 330
18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 330
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 331
18.5.1 STARS 331
18.5.2 EMERGING LEADERS 331
18.5.3 PERVASIVE PLAYERS 331
18.5.4 PARTICIPANTS 332
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 333
18.5.5.1 Company footprint 333
18.5.5.2 Region footprint 333
18.5.5.3 Product & service footprint 334
18.5.5.4 Indication footprint 335
18.5.5.5 Technology footprint 335
 
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 336
18.6.1 PROGRESSIVE COMPANIES 336
18.6.2 RESPONSIVE COMPANIES 336
18.6.3 DYNAMIC COMPANIES 336
18.6.4 STARTING BLOCKS 336
18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 337
18.6.5.1 Detailed list of key startups/SMEs 337
18.6.5.2 Competitive benchmarking of startups/SMEs 338
18.7 COMPANY VALUATION & FINANCIAL METRICS 339
18.7.1 FINANCIAL METRICS 339
18.7.2 COMPANY VALUATION 339
18.8 BRAND/PRODUCT COMPARISON 340
18.9 COMPETITIVE SCENARIO 341
18.9.1 PRODUCT LAUNCHES & APPROVALS 341
18.9.2 DEALS 342
18.9.3 EXPANSIONS 343
18.9.4 OTHER DEVELOPMENTS 343
19 COMPANY PROFILES 344
19.1 KEY PLAYERS 344
19.1.1 F. HOFFMANN-LA ROCHE LTD. 344
19.1.1.1 Business overview 344
19.1.1.2 Products/Services/Solutions offered 345
19.1.1.3 Recent developments 347
19.1.1.3.1 Product launches & approvals 347
19.1.1.3.2 Deals 349
19.1.1.3.3 Expansions 349
19.1.1.4 MnM view 349
19.1.1.4.1 Key strengths 349
19.1.1.4.2 Strategic choices 350
19.1.1.4.3 Weaknesses & competitive threats 350
19.1.2 AGILENT TECHNOLOGIES, INC 351
19.1.2.1 Business overview 351
19.1.2.2 Products/Services/Solutions offered 352
19.1.2.3 Recent developments 353
19.1.2.3.1 Product launches & approvals 353
19.1.2.3.2 Deals 354
19.1.2.4 MnM view 354
19.1.2.4.1 Key strengths 354
19.1.2.4.2 Strategic choices 355
19.1.2.4.3 Weaknesses & competitive threats 355
 
19.1.3 QIAGEN 356
19.1.3.1 Business overview 356
19.1.3.2 Products/Services/Solutions offered 357
19.1.3.3 Recent developments 358
19.1.3.3.1 Product launches & approvals 358
19.1.3.3.2 Deals 359
19.1.3.3.3 Expansions 359
19.1.3.4 MnM view 360
19.1.3.4.1 Key strengths 360
19.1.3.4.2 Strategic choices 360
19.1.3.4.3 Weaknesses & competitive threats 360
19.1.4 THERMO FISHER SCIENTIFIC INC. 361
19.1.4.1 Business overview 361
19.1.4.2 Products/Services/Solutions offered 362
19.1.4.3 Recent developments 364
19.1.4.3.1 Product launches 364
19.1.4.3.2 Deals 364
19.1.4.4 MnM view 365
19.1.4.4.1 Key strengths 365
19.1.4.4.2 Strategic choices 365
19.1.4.4.3 Weaknesses & competitive threats 365
19.1.5 ABBOTT 366
19.1.5.1 Business overview 366
19.1.5.2 Products/Services/Solutions offered 367
19.1.5.3 Recent developments 368
19.1.5.3.1 Product approvals 368
19.1.5.3.2 Deals 369
19.1.5.4 MnM view 369
19.1.5.4.1 Key strengths 369
19.1.5.4.2 Strategic choices 369
19.1.5.4.3 Weaknesses & competitive threats 370
19.1.6 DANAHER 371
19.1.6.1 Business overview 371
19.1.6.2 Products/Services/Solutions offered 372
19.1.6.3 Recent developments 373
19.1.6.3.1 Product approvals 373
19.1.6.3.2 Deals 373
19.1.6.4 MnM view 373
19.1.6.4.1 Key strengths 373
19.1.6.4.2 Strategic choices 374
19.1.6.4.3 Weaknesses & competitive threats 374
 
19.1.7 ILLUMINA, INC. 375
19.1.7.1 Business overview 375
19.1.7.2 Products/Services/Solutions offered 376
19.1.7.3 Recent developments 377
19.1.7.3.1 Product launches & approvals 377
19.1.7.3.2 Deals 377
19.1.8 BIOMÉRIEUX 378
19.1.8.1 Business overview 378
19.1.8.2 Products/Services/Solutions offered 379
19.1.8.3 Recent developments 379
19.1.8.3.1 Deals 379
19.1.9 MYRIAD GENETICS, INC. 380
19.1.9.1 Business overview 380
19.1.9.2 Products/Services/Solutions offered 381
19.1.9.3 Recent developments 382
19.1.9.3.1 Product launches & approvals 382
19.1.9.3.2 Deals 382
19.1.10 SYSMEX CORPORATION 384
19.1.10.1 Business overview 384
19.1.10.2 Products/Services/Solutions offered 385
19.1.10.3 Recent developments 386
19.1.10.3.1 Deals 386
19.1.11 QUEST DIAGNOSTICS 387
19.1.11.1 Business overview 387
19.1.11.2 Products/Services/Solutions offered 388
19.1.11.3 Recent developments 389
19.1.11.3.1 Deals 389
19.1.12 GUARDANT HEALTH 390
19.1.12.1 Business overview 390
19.1.12.2 Products/Services/Solutions offered 391
19.1.12.3 Recent developments 392
19.1.12.3.1 Product launches & approvals 392
19.1.13 ICON PLC 394
19.1.13.1 Business overview 394
19.1.13.2 Products/Services/Solutions offered 395
19.1.14 TEMPUS AI, INC. 396
19.1.14.1 Business overview 396
19.1.14.2 Products/Services/Solutions offered 397
19.1.14.3 Recent developments 397
19.1.14.3.1 Deals 397
19.1.14.3.2 Other developments 397
 
19.1.15 CARIS LIFE SCIENCES, INC. 398
19.1.15.1 Business overview 398
19.1.15.2 Products/Services/Solutions offered 399
19.1.15.3 Recent developments 400
19.1.15.3.1 Product launches & approvals 400
19.2 OTHER PLAYERS 401
19.2.1 THE ALMAC GROUP 401
19.2.2 AMOY DIAGNOSTICS CO., LTD. 401
19.2.3 ARUP LABORATORIES 402
19.2.4 ABNOVA CORPORATION 402
19.2.5 INVIVOSCRIBE, INC. 403
19.2.6 Q² SOLUTIONS 403
19.2.7 CREATIVE BIOLABS 404
19.2.8 PILLAR BIOSCIENCES 404
19.2.9 ENTROGEN, INC. 405
19.2.10 BIOCARTIS 405
20 RESEARCH METHODOLOGY 406
20.1 RESEARCH DATA 406
20.1.1 SECONDARY DATA 407
20.1.1.1 List of secondary sources 407
20.1.1.2 Key data from secondary sources 408
20.1.2 PRIMARY DATA 408
20.1.2.1 List of primary sources 409
20.1.2.2 Key data from primary sources 409
20.1.2.3 Key industry insights 410
20.1.2.4 Breakdown of primary interviews 411
20.2 MARKET SIZE ESTIMATION 411
20.2.1 TOTAL MARKET SIZE: COMPANION DIAGNOSTICS MARKET 411
20.2.2 BOTTOM-UP APPROACH 411
20.2.2.1 Approach 1: Revenue estimation of key players 412
20.2.2.2 Approach 2: Study of annual reports and investor presentations 412
20.2.2.3 Approach 3: Primary interviews 412
20.2.2.4 Growth forecast 412
20.2.2.5 CAGR projections 413
20.2.3 TOP-DOWN APPROACH 414
20.3 DATA TRIANGULATION 415
20.4 RESEARCH ASSUMPTIONS 415
20.4.1 STUDY-RELATED ASSUMPTIONS 415
20.5 STUDY ASSUMPTIONS 416
20.5.1 PARAMETRIC ASSUMPTIONS 416
20.5.2 GROWTH RATE ASSUMPTIONS 417
20.6 RESEARCH LIMITATIONS 417
20.7 RISK ASSESSMENT 417
21 APPENDIX 418
21.1 DISCUSSION GUIDE 418
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 423
21.3 CUSTOMIZATION OPTIONS 425
21.4 RELATED REPORTS 425
21.5 AUTHOR DETAILS 426